Obinutuzumab in the treatment of a patient with Waldenström macroglobulinemia and rituximab intolerance: a case report

Czech version

Authors: Z. Adam; M. Krejčí; L. Pour; M. Štork; V. Sandecká; Z. Král
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno
Published in: Transfuze Hematol. dnes,1, 2020, No. Preview preliminary publication, p. 1-15.
Category:

Overview

Obinutuzumab is a new anti-CD20 monoclonal antibody predominantly used in the treatment of patients with chronic lymphocytic leukaemia and follicular lymphoma. In our case report, we describe successful treatment using obinutuzumab in a patient with Waldenström macroglobulinemia. This therapy was used as 4^th line-treatment and led to complete biochemical and clinical response of Waldenström macroglobulinemia. Obitunuzumab could thus be useful option even in such a rare disease.

Keywords:

obinutuzumab – Waldenström macroglobulinemia

Sources

Hájek R. Diagnostika a léčba Waldenströmovy makroglobulinemie. Transfuze Hematol Dnes. 2019;25(Suppl 1):7–33.
Adam Z, Hájek R, Krejčí M., et al. Diagnostika a léčba Waldenströmovy makroglobulinemie : doplněk č. 1 k doporučení z 9/2012 Diagnostika a léčba mnohočetného myelomu. Transfuze Hematol Dnes. 2014;20(Suppl):7–22.
Sakalová A, Škultétyová D, Konečná Z., et al. Súčasná klasifikácia, diagnostika a prognóza primárnych monoklonových gamapatií (paraproteinémií). Transfuze Hematol Dnes. 2010;16:193–201.
Adam Z, Koukalová R, Krejčí M., et al. Chronická recidivující kopřivka, bolesti kostí i kloubů, horečka nejasného původu a monoklonální imunoglobulin typu IgM = syndrom Schnitzlerové Transfuze Hematol Dnes. 2018;24:88–103.
Gavriatopoulou M, Musto P, Hájek R, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32:1883–1898.
Tichý M, Maisnar V. Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu. 1. vyd. Praha: Nucleus HK, 2012;9–16.
Kaščák M, Ďuraš J, Navrátil M, et al. Autologní transplantace kmenových buněk u Waldenströmovy makroglobulinemie. Transfuze Hematol Dnes. 2016;22:28–38.
Ščudla V, Minařík J, Pika T, et al. Diferenciální diagnostika monoklonálních gamapatií z pohledu klinické praxe. Int Med Prax. 2017;19:274–278.
Pika T, Flodr P, Novák M, et al. Klinická problematika IgM monoklonálních gamapatií. Klin Bioch Metabol. 2014;22:61–64.
Ševčíková S, Novák L, Beše L, et al. Molekulární podstata Waldenströmovy makroglobulinemie. Klin Onkol. 2012;25:413–420.
Salles GA, Morschhauser F, Solal-Céligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the Phase II GAUGUIN study. J Clin Oncol. 2013;31:2920–2926.
Tomowiak C, Poulain S, Debiais C, et al. Idelalisib and obinutuzumab in relapsed or refraktory Waldenström´s macroglobulinaemia. Blood 2019;134(Suppl 1):346.
Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–2042.
Mössner E, Brünker P, Moser P, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new Type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 2010;115:4393–4402.
Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016;128:1321–1328.
Gavriatopoulou M, Kastritis E, Kyrtsonis MC, et al. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Leuk Lymphoma. 2017;58:1506–1508.
Furman RR, Eradat HA, DiRienzo CG, et al. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017;4:e24–e34.
Buske C. Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia? Lancet Haematol. 2017;4:e4–e5.
Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–1093.
García-Muñoz R, López-Díaz-de-Cerio A, Feliu J, et al. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity. Immunol Res. 2016;64:548–557.
Sehn LH, Goy A, Offner FC, et al. Randomized Phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B cell non-hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33:3467–3474.
Marcus R, Devies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–1344.
Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the randomized Phase III GALLIUM study: influence of chemotherapy regimen on efficacy and safety. J Clin Oncol. 2018;36:2395–2404.
Friedberg JW. Progress in advanced-stage follicular lymphoma. J Clin Oncol. 2018;36:2363–2365.
Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104:1202–1208.
Jamois C, Gibiansky E, Gibiansky L, et al. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. Br J Clin Pharmacol. 2019;85:1495–1506.
Freeman CL, Morschhauser F, Sehn L, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126:2646–2649.
Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study. Blood. 2013;122:1137–1143.
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
Kusumoto S, Tobinai K. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematology 2014. 2014;1:576–583.
Hadrabová M, Doubek M. Obinutuzumab. Remedia. 2016;26:44–48.
Zuchnická J, Fečková-Mihályová J, Hájek R. Obinutuzumab v první linii léčby chronické lymfocytární leukemie ‒ zkušenosti z klinické praxe. Remedia. 2018;28:377–381.
Belada D. Obinutuzumab v léčbě nehodgkinských B lymfomů – studie GADOLIN. Remedia. 2015;25:375–378.
Šimkovič M. Obinutuzumab dosáhl v kombinaci s chlorambucilem ve srovnání s rituximabem zlepšení celkového přežití komorbidních pacientů s chronickou lymfocytární leukemií: finální analýza přežití ve studii CLL11. Transfuze Hematol Dnes. 2018;24:129–130.

Labels

Haematology Internal medicine Clinical oncology

Pitfalls of treating chronic myeloid leukaemia with dasatinib – pulmonary arterial hypertension as a rare complication

A peripherally inserted central catheter is a safe means of ensuring long-term central venous access in patients with acute leukaemia – a single centre experience

POEMS syndrome – a rare disease associated with monoclonal gammopathy and polyneuropathy: diagnosis and treatment

Article was published in

Transfusion and Haematology Today

2020 Issue Preview preliminary publication